The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic in...
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry
About this item
Full title
Author / Creator
Publisher
Germany: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Germany: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
RRx-001, a dinitroazetidine derivative, is a novel anticancer agent currently in phase II clinical trials. It mediates immunomodulatory effects either directly through polarization of tumor associated macrophages or indirectly through vascular normalization and increased T-lymphocyte infiltration. With multiple additional mechanisms of action inclu...
Alternative Titles
Full title
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5270305
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5270305
Other Identifiers
ISSN
1868-7075,1868-7083
E-ISSN
1868-7083,1868-7075
DOI
10.1186/s13148-017-0312-z
